Pentostatin (Nipent) and high-dose cycloposphamide for the treatment of refractory autoimmune disorders

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Autoimmune rheumatologic diseases has a wide range of clinical expression that occasionaly can be disabling. Patients with visceral organ involvement are exposed to significant morbidity and mortality if effective therapy is not forthcoming. The mainstay of therapy has been immunosuppression. However, some patients fail to respond to conventional doses of corticosteriods, methotrexate, or cyclophosphamide, and new approaches are needed for these patients. One new approach involves the use of intensified immunosuppression by combining cyclophosphamide with purine nucleoside analogs, including the adenosine deaminase inhibitor pentostatin (Nipent; Super Gen, San Ramon, CA). Copyright (C) 2000 by W.B. Saunders Company.

Original languageEnglish (US)
Pages (from-to)67-71
Number of pages5
JournalSeminars in Oncology
Volume27
Issue number3 SUPPL. 5
StatePublished - Jul 12 2000

    Fingerprint

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this